← All trials
NCT01926444
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2013
- Primary completion
- Mar 1, 2014
- Completion date
- Mar 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 308
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- gicare Pharma Inc.Lead sponsor
- Anaheim Clinical TrialsOverall official - principal investigator
- The Center of GI Disorders, Hollwood, FL, USAOverall official - principal investigator
- Toronto Digestive Disease Associates, Toronto, ON, CanadaOverall official - principal investigator
- PharmaTrialsOverall official - principal investigator
- Gastroenterology Associates of Orangeburg, SCOverall official - principal investigator
- Mid-Atlantic Medical Research Centers, Hollyword, MDOverall official - principal investigator
- Precision Research InstituteOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- Anaheim Clinical TrialsStudy director
- Mayo ClinicStudy chair
- University of British ColumbiaOverall official - principal investigator
- JSS Medical Research Inc.Collaborator
- Algorithme Pharma IncCollaborator
- Avail Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.